Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147-2160. doi:10.1007/s12325-019-00991-w.

Adv Ther · 2020 · PMC6999160 · PMID 31838710

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

concluded that InO had superior efficacy in terms of rates of remission and hematopoietic stem cell transplantation (HSCT) and a favorable trend on event-free survival (EFS) compared to blinatumomab.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.